Your browser doesn't support javascript.
loading
Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice.
Yumita, Sae; Ogasawara, Sadahisa; Nakagawa, Miyuki; Maruta, Susumu; Okubo, Tomomi; Itokawa, Norio; Iino, Yotaro; Obu, Masamichi; Haga, Yuki; Seki, Atsuyoshi; Kogure, Tadayoshi; Ishino, Takamasa; Ogawa, Keita; Fujiwara, Kisako; Iwanaga, Terunao; Fujita, Naoto; Sakuma, Takafumi; Kojima, Ryuta; Kanzaki, Hiroaki; Koroki, Keisuke; Inoue, Masanori; Kobayashi, Kazufumi; Kiyono, Soichiro; Nakamura, Masato; Kanogawa, Naoya; Saito, Tomoko; Kondo, Takayuki; Nakagawa, Ryo; Nakamoto, Shingo; Muroyama, Ryosuke; Chiba, Tetsuhiro; Itobayashi, Ei; Atsukawa, Masanori; Koma, Yoshihiro; Azemoto, Ryosaku; Ito, Kenji; Mizumoto, Hideaki; Kato, Jun; Kato, Naoya.
Afiliação
  • Yumita S; Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-Ku, Chiba, Japan.
  • Ogasawara S; Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-Ku, Chiba, Japan. ogasawaras@chiba-u.jp.
  • Nakagawa M; Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-Ku, Chiba, Japan.
  • Maruta S; Department of Gastroenterology, Asahi General Hospital, Asahi, Japan.
  • Okubo T; Department of Gastroenterology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.
  • Itokawa N; Department of Gastroenterology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.
  • Iino Y; Department of Internal Medicine, Division of Gastroenterology and Hepatology, Nippon Medical School, Tokyo, Japan.
  • Obu M; Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-Ku, Chiba, Japan.
  • Haga Y; Department of Gastroenterology, Kimitsu Chuo Hospital, Kisarazu, Japan.
  • Seki A; Department of Gastroenterology, Kimitsu Chuo Hospital, Kisarazu, Japan.
  • Kogure T; Department of Gastroenterology, National Hospital Organization Chiba Medical Center, Chiba, Japan.
  • Ishino T; Department of Gastroenterology, Funabashi Municipal Medical Center, Funabashi, Japan.
  • Ogawa K; Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-Ku, Chiba, Japan.
  • Fujiwara K; Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-Ku, Chiba, Japan.
  • Iwanaga T; Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-Ku, Chiba, Japan.
  • Fujita N; Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-Ku, Chiba, Japan.
  • Sakuma T; Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-Ku, Chiba, Japan.
  • Kojima R; Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-Ku, Chiba, Japan.
  • Kanzaki H; Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-Ku, Chiba, Japan.
  • Koroki K; Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-Ku, Chiba, Japan.
  • Inoue M; Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-Ku, Chiba, Japan.
  • Kobayashi K; Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-Ku, Chiba, Japan.
  • Kiyono S; Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-Ku, Chiba, Japan.
  • Nakamura M; Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-Ku, Chiba, Japan.
  • Kanogawa N; Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-Ku, Chiba, Japan.
  • Saito T; Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-Ku, Chiba, Japan.
  • Kondo T; Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-Ku, Chiba, Japan.
  • Nakagawa R; Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-Ku, Chiba, Japan.
  • Nakamoto S; Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-Ku, Chiba, Japan.
  • Muroyama R; Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-Ku, Chiba, Japan.
  • Chiba T; Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-Ku, Chiba, Japan.
  • Itobayashi E; Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-Ku, Chiba, Japan.
  • Atsukawa M; Department of Gastroenterology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-Ku, Chiba, Japan.
  • Koma Y; Department of Gastroenterology, Asahi General Hospital, Asahi, Japan.
  • Azemoto R; Department of Gastroenterology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.
  • Ito K; Department of Internal Medicine, Division of Gastroenterology and Hepatology, Nippon Medical School, Tokyo, Japan.
  • Mizumoto H; Department of Gastroenterology, Kimitsu Chuo Hospital, Kisarazu, Japan.
  • Kato J; Department of Gastroenterology, Kimitsu Chuo Hospital, Kisarazu, Japan.
  • Kato N; Department of Gastroenterology, National Hospital Organization Chiba Medical Center, Chiba, Japan.
BMC Gastroenterol ; 23(1): 101, 2023 Mar 31.
Article em En | MEDLINE | ID: mdl-37003980
ABSTRACT

BACKGROUND:

Hyperprogressive disease (HPD) is a phenomenon with greatly accelerated tumor growth and clinical deterioration rates compared to pre-therapy, in patients treated with immune checkpoint inhibitors (ICI). The aim of this study is to clarify the reality of HPD in patients with advanced hepatocellular carcinoma (HCC) who were treated with atezolizumab plus bevacizumab (Atez/Bev) using tumor dynamics.

METHODS:

Medical records of consecutive patients with advanced HCC who were treated with Atez/Bev were retrospectively reviewed. HPD was defined as a more than two- or fourfold increase in tumor growth rate (TGR) or tumor growth kinetics rate (TGKR) before and after treatment. Overall survival (OS) and baseline characteristics with or without HPD were analyzed.

RESULTS:

A total of 85 patients were included in the analysis. When HPD was defined as a twofold of TGR or TGKR, 8 patients (8/85, 9.4%) had HPD and 11 had PD without HPD. A total of 5 patients (5/85, 5.9%) were diagnosed with HPD and 14 with PD without HPD when HPD was defined as a fourfold of TGR or TGKR. No significant difference was observed in the baseline characteristics between HPD and non-HPD.

CONCLUSION:

The prevalence of HPD in patients with advanced HCC treated with Atez/Bev was lower than those treated with nivolumab monotherapy. The HPD mechanism in ICI combined with antibodies targeting vascular endothelial growth factor (VEGF) remains to be elucidated.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: BMC Gastroenterol Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Japão
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: BMC Gastroenterol Assunto da revista: GASTROENTEROLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Japão